Announced the initiation of the pharmacokinetic/pharmacodynamic study of otenaproxesul’s faster-absorbing formulation for acute pain. The study is designed to inform the doses and confirm safety in preparation for the Phase II trial, on track to launch in calendar Q1 2024. Antibe Therapeutics Inc shares T.ATE are trading unchanged at $0.45.
Stocks in play: Antibe Therapeutics Inc
Baystreet.ca - Baystreet - Contributor Content
This article could contain syndicated content. We have not reviewed, approved, or endorsed the content and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here
/Technology%20abstract%20by%20TU%20IS%20via%20iStock.jpg)